STING
Stimulator of Interferon Genes; TMEM173; MITA; ERIS; MPYS
Stimulator of interferon genes (STING) is an integral ER-membrane protein that can be activated by 2'3'-cGAMP synthesized by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) upon binding of double-stranded DNA. It activates interferon (IFN) and inflammatory cytokine responses to defend against infection by microorganisms.
STING is a key cytosolic receptor for small nucleotides and plays a key role in anticancer and antiviral immunity. STING signaling pathway is also a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING agonists, such as endogenous cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP), have been used in diverse research for immunogenic tumor clearance, antiviral treatments and vaccine adjuvants.
All Product Categories
-
STING Inhibitors
(51)
View all products
-
STING Agonists
(105)
View all products
-
STING Antagonists
(7)
View all products
-
STING Activators
(50)
View all products
-
STING Modulators
(5)
View all products
-
STING Degraders
(12)
View all products
-
STING Controls
(3)
View all products
-
STING Ligands
(3)
View all products
-
STING Related Products (253)
Related Products (253)
-
Antibodies (13)
-
SAP-04
0 ImagesCat. No.: HY-156290CAS No.: 3053678-30-8
-
3′,5′-DiOA-dC
0 ImagesCat. No.: HY-1725333’,5’-DiOA-dC is a hydrophobic nucleotide lipid and a ligand for the STING agonist c-di-GMP (CDG). 3’,5’-DiOA-dC can assemble with CDG and form stable cyclic dinucleotide nanoparticles via various supramolecular forces driven by molecular recognition. 3’,5’-DiOA-dC can decrease tumor weight and volume, increase CD8 T cell, neutrophils as well as NK cell counts in tumor microenvironment in combination with CDG. 3’,5’-DiOA-dC also increases the levels of TNF-α and IFN-γ in murine melanoma model.
-
(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide
![(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide](https://file.medchemexpress.com/product_pic/hy-174170.gif "Click to View (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide Product Detail")
0 ImagesCat. No.: HY-174170CAS No.: 2248444-14-4(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide (compound 4) is a STING agonist containing a key amide benzimidazole (ABZI) component and shows reproducible inhibition of 3H-cGAMP binding to STING with an apparent inhibition constant IC50 of 14 μM. (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide can be used for tumor research.
-
hSTING activator-1
0 ImagesCat. No.: HY-173399hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC50 values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research.
-
STING agonist-43
0 ImagesCat. No.: HY-172671CAS No.: 2882097-31-4STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity.
-
ZSA-215
0 ImagesCat. No.: HY-174308ZSA-215 is a potent and orally active STING agonist with an EC50 of 3.3 μM. ZSA-215 enhances STING signaling through promoting the phosphorylation of STING and interferon regulatory factor 3 (IRF3) and secretion of IFN-β. ZSA-215 inhibits tumor regression and long-term survival of mice in MC38 colon cancer model. ZSA-215 can be used to the study of colon cancerr.
-
STING agonist-25
0 ImagesCat. No.: HY-152958CAS No.: 2408723-10-2STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
-
TLC388
0 ImagesCat. No.: HY-19943CAS No.: 1432468-79-5TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC.
-
STING agonist-30
0 ImagesCat. No.: HY-149267CAS No.: 2951078-67-2
-
STING agonist-48
0 ImagesCat. No.: HY-178966CAS No.: 3027712-31-5STING agonist-48 is a potent STING agonist that exhibits STING-dependent activity in vitro (EC50 = 4.02 μM). STING agonist-48 prefers to bind with the transmembrane domain (TMD) over the cytosolic cyclic dinucleotide (CDN) domain. STING agonist-48 shows adjuvant efficacy, enhancing IgG and Th1/Th2 cytokine responses in humanized STING mice. STING agonist-48 can be used for the study of inflammation-related diseases.
-
Vadimezan (Standard)
0 ImagesSynonyms: DMXAA (Standard); ASA-404 (Standard)Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
-
Ulevostinag (isomer 2)
0 ImagesCat. No.: HY-139586BCAS No.: 2082743-99-3Synonyms: MK-1454 (isomer 2)Ulevostinag isomer 2 (MK-1454 isomer 2) is the isomer of Ulevostinag. Ulevostinag is a STING agonist.
-
STING agonist-3 (Standard)
0 ImagesSTING agonist-3 (Standard) is the analytical standard of STING agonist-3 (HY-103665). This product is intended for research and analytical applications. STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
